Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
CAN016 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
CAN016: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
EIK-1005 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
EIK-1005: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
QR-059349 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
QR-059349: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
GD2/mesothelin Dual-Target CAR-NK(Beijing Biotech) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
GD2/mesothelin Dual-Target CAR-NK(Beijing Biotech): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, ma
9 min read
NerveTrace Dx Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
NerveTrace Dx: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Mesenchymal Stem Cells Derived Exosomes(Isfahan University of Medical Sciences): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical develop
9 min read
BCMA CAR-T cells(Shenzhen Geno-Immune Medical Institute) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BCMA CAR-T cells(Shenzhen Geno-Immune Medical Institute): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing dea
9 min read
Anti BCMA CAR-T Cell(Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Anti BCMA CAR-T Cell(Minsk Scientific and Practical Center for Surgery, Transplantology and Hematology): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review
9 min read
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Recombinant anti-HER2 humanized HuA21 monoclonal antibody(Hefei Hankemab Biotechnology Co Ltd): Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers c
9 min read
ICP-B381 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
ICP-B381: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII(University of Manchester): Phase 1/2. 2026 diligence verdict: HOLD / OPTION.
9 min read
BRT-OpCT-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
28 September 2026
BRT-OpCT-001: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.